September 30, 2025 — Leads & Copy — Aurion Biotech, a clinical-stage regenerative medicine company, has announced the promotions of Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer. These appointments come as the company prepares for a U.S. Phase 3 clinical trial in Q1 2026.
Aurion Biotech is developing AURN001, a single-administration, allogeneic cell therapy for corneal endothelial disease, which causes vision loss in millions.
“I’m proud to announce the promotions of Andrew Torres and Sterling Chung to Aurion Biotech’s executive team, signaling a new phase of growth as we prepare to launch a U.S. Phase 3 clinical trial in the first quarter of 2026 for our groundbreaking cell therapy AURN001,” said Arnaud Lacoste, CEO and CSO of Aurion Biotech. He added that their experience in pharmaceuticals and biologics development, along with their regulatory navigation skills, will help Aurion achieve its mission.
Torres will lead the global manufacturing program for Aurion’s cell therapy, while Chung will oversee global regulatory affairs and quality, building on his track record of regulatory achievements in the U.S., Canada, Europe, and Central America, as well as post-approval activities in Japan.
Andrew Torres, Chief Manufacturing Officer, Aurion Biotech.
Contact:
Andrew Torres
Source: Aurion Biotech
